AbbVie Inc.
Therapeutic DLL4 Binding Proteins
Last updated:
Abstract:
DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
Status:
Application
Type:
Utility
Filling date:
28 Apr 2017
Issue date:
17 Oct 2019